Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 6, 2010, Pages

  Prenner, Bruce M ^a   Lanier, Bobby Q ^b   Bernstein, David I ^c   Shekar, Tulin ^d   Teper, Ariel ^d  

^a Allergy Associates Medical Group Inc   (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allergic rhinitis; intranasal corticosteroids; mometasone furoate nasal spray

Indexed keywords

MOMETASONE FUROATE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EPIPHORA; EPISTAXIS; EYE DISEASE; FEMALE; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE DISEASE; OCULAR PRURITUS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM; TREATMENT RESPONSE;

EID: 77952741586     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.03.004     Document Type: Article

References (69)

1. Naclerio R.M. Allergic rhinitis. N Engl J Med 325 (1991) 860-869
2. Bacon A.S., Ahluwalia P., Irani A.-M., Schwartz L.B., Holgate S.T., Church M.K., et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J Allergy Clin Immunol 106 (2000) 948-954
3. Skoner D.P. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108 suppl 1 (2001) S2-S8
4. Bonini S. Allergic conjunctivitis: the forgotten disease. Chem Immunol Allergy 91 (2006) 110-120
5. Blaiss M.S. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids. Curr Med Res Opin 24 (2008) 821-836
6. Wüthrich B., Brignoli R., Canevascini M., and Gerber M. Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweiz Med Wochenschr 128 (1998) 139-143
7. Canonica G.W., Bousquet J., Mullol J., Scadding G.K., and Virchow J.C. A survey of the burden of allergic rhinitis in Europe. Allergy 62 suppl 85 (2007) 17-25
8. Scadding G.K., Durham S.R., Mirakian R., Jones N.S., Leech S.C., Farooque S., et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 38 (2008) 19-42
9. Allergies in America: A Landmark Survey of Nasal Allergy Sufferers. Available at: http://www.myallergiesinamerica.com. Accessed December 12, 2008.
10. Pitt A.D., Smith A.F., Lindsell L., Voon L.W., Rose P.W., and Bron A.J. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 11 (2004) 17-33
11. Frieri M., Therattil J., Chavarria V., Cosachov J., Kumar N.S., Wang S.F., et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 81 (1998) 431-437
12. Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., Togias A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 63 suppl 86 (2008) 8-160
13. Price D., Bond C., Bouchard J., Costa R., Keenan J., Levy M.L., et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Respir J 15 (2006) 58-70
14. Rosenwasser L., Mahr T., Abelson M., Gomes P., and Kennedy K. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy Asthma Proc 29 (2008) 644-653
15. Spangler D.L., Abelson M.B., Ober A., and Gomes P.J. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 25 (2003) 2245-2267
16. Butrus S., Greiner J.V., Discepola M., and Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 22 (2000) 1462-1472
17. Greiner J.V., and Minno G. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model. Clin Ther 25 (2003) 1988-2005
18. Katelaris C.H., Ciprandi G., Missotten L., Missotten L., Turner F.D., Bertin D., et al. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 24 (2002) 1561-1575
19. James I.G., Campbell L.M., Harrison J.M., Fell P.J., Ellers-Lenz B., and Petzold U. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 19 (2003) 313-320
20. Alexander M., Allegro S., and Hicks A. Efficacy and acceptability of nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis. Adv Ther 17 (2000) 140-147
21. Bousquet J., Van Cauwenberge P., Khaltaev N., Aria Workshop Group, and World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108 suppl (2001) S147-S334
22. Anolik R., and for the Mometasone Furoate Nasal Spray With Loratadine Study Group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100 (2008) 264-271
23. Benincasa C., and Lloyd R.S. Evaluation of fluticasone propionate aqueous nasal spray taken alone and in combination with cetirizine in the prophylactic treatment of seasonal allergic rhinitis. Drug Invest 8 (1994) 225-233
24. Di Lorenzo G., Pacor M.L., Pellitteri M.E., Morici G., Di Gregoli A., Lo Bianco C., et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 34 (2004) 259-267
25. Weiner J.M., Abramson M.J., and Puy R.M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 317 (1998) 1624-1629
26. Yáňez A., and Rodrigo G.J. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 89 (2002) 479-484
27. Ratner P.H., Hampel F., van Bavel J.H., Amar N.J., Daftary P., Wheeler W., et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone proprionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100 (2008) 74-81
28. DeWester J., Philpot E.E., Westlund R.E., Cook C.K., and Rickard K.A. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 24 (2003) 331-337
29. Bernstein D.I., Levy A.L., Hampel F.C., Baidoo C.A., Cook C.K., Philpot E.E., et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 34 (2004) 952-957
30. Fokkens W.J., Jogi R., Reinartz S., Sidorenko I., Sitkauskiene B., van Oene C., et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 62 (2007) 1078-1084
31. Kaiser H.B., Naclerio R.M., Given J., Toler T.N., Ellsworth A., and Philpot E.E. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 119 (2007) 1430-1437
32. Bronsky E.A., Aaronson D.W., Berkowitz R.B., Chervinsky P., Graft D., Kaiser H.B., et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 79 (1997) 51-56
33. Berkowitz R.B., Bernstein D.I., LaForce C., Pedinoff A.J., Rooklin A.R., Damaraju C.R.V., et al. Onset of action of mometasone furoate nasal spray (NASONEX®) in seasonal allergic rhinitis. Allergy 54 (1999) 64-69
34. Meltzer E.O., Berger W.E., Berkowitz R.B., Bronsky E.A., Dvorin D.J., Finn A.F., et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 104 (1999) 107-114
35. Anolik R., Nathan R.A., Schenkel E., Danzig M.R., Gates D., and Varghese S. Intranasal mometasone furoate alleviates the ocular symptoms associated with seasonal allergic rhinitis: results of a post hoc analysis. Int Arch Allergy Immunol 147 (2008) 323-330
36. Sussman G., Gates D., and Danzig M. Total ocular symptom scores in patients with seasonal allergic rhinitis are reduced with mometasone furoate nasal spray. J Allergy Clin Immunol 119 suppl 1 (2007) S61
37. Hébert J., Gates D., and Danzig M. Mometasone furoate improves total ocular symptom score in subjects with seasonal allergic rhinitis. J Allergy Clin Immunol 119 suppl 1 (2007) S61
38. Schenkel E., LaForce C., and Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis. Effective in relieving ocular symptoms. Allergy Clin Immunol Int-J World Allergy Org 19 (2007) 50-53
39. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 100 (2008) 272-279
40. Juniper E.F., Thompson A.K., Ferrie P.J., and Roberts J.N. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 104 (1999) 364-369
41. Juniper E.F., Guyatt G.H., Griffith L.E., and Ferrie P.J. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98 (1996) 843-845
42. Jacobson M.R., Juliusson S., Löwhagen O., Balder B., Kay A.B., and Durham S.R. Effect of topical corticosteroids on seasonal increases in epithelial eosinophils and mast cells in allergic rhinitis: a comparison of nasal brush and biopsy methods. Clin Exp Allergy 29 (1999) 1347-1355
43. Bernstein D. Long-term ocular safety of mometasone furoate nasal spray during treatment of perennial rhinitis. Allergy 63 suppl 88 (2008) 87
44. Cave A., Arlett P., and Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 83 (1999) 153-179
45. Oztürk F., Yücetürk A.V., Kurt E., Unlü H.H., and Ilker S.S. Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids. Ear Nose Throat J 77 (1998) 846-848
46. Naclerio R.M., and Philpot E.E. Is conjunctival allergen challenge a model of seasonal rhinoconjunctivitis?. Allergy Asthma Proc 30 (2009) 212-213
47. Philip G., Baroody F.M., Proud D., Naclerio R.M., and Togias A.G. The human nasal response to capsaicin. J Allergy Clin Immunol 94 (1994) 1035-1045
48. Casale T.B., Romero F.A., and Spierings E.L.H. Intranasal noninhaled carbon dioxide for the symptomatic treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 121 (2008) 105-109
49. Bowen E.J., Niemann C.C., and Durham P.L. Carbon dioxide regulation of CGRP secretion from trigeminal neurons. [abstract]. Headache 45 suppl (2005) 808
50. Bellamy J.L., Cady R.K., and Durham P.L. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 46 (2006) 24-33
51. Undem B.J., Kajekar R., Hunter D.D., and Myers A.C. Neural integration and allergic disease. J Allergy Clin Immunol 106 suppl (2000) S213-S220
52. Naclerio R.M., Pinto J., deTineo M., and Baroody F.M. Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc 29 (2008) 24-28
53. Baroody F.M., Foster K.A., Markaryan A., deTineo M., and Naclerio R.M. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 100 (2008) 194-199
54. Pipkorn U., Proud D., Kichtenstein L.M., Kagey-Sobotka A., Norman P.S., and Naclerio R.M. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 316 (1987) 1506-1510
55. Svensson C., Andersson M., Greiff L., Blychert L.-O., and Persson C.G. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation response in seasonal allergic rhinitis. Allergy 53 (1998) 367-374
56. Cohen AJ, Mercandetti M, Brazzo BG. The lacrimal system; diagnosis, management, and surgery. Available at: http://www.dentaldad.com/ddbooks/the_lacrimal_system.pdf. Accessed April 24, 2009.
57. McNeill E.J., Kubba H., Bearn M.A., and Robson A.K. The management of rhinitis in patients with functional epiphora: a randomized controlled crossover trial. Am J Rhinol 19 (2005) 588-590
58. Meltzer E.O., Rickard K.A., Westlund R.E., and Cook C.K. Onset of therapeutic effect of fluticasone propionate aqueous nasal spray. Ann Allergy Asthma Immunol 86 (2001) 286-291
59. Long A.A. Findings from a 1000-patient internet-based survey assessing the impact of morning symptoms on individuals with allergic rhinitis. Clin Ther 29 (2007) 342-351
60. Keith P.K., and Scadding G.K. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis?. Curr Med Res Opin 25 (2009) 2021-2041
61. Bielory L. Intranasal corticosteroids reduce ocular symptoms of allergic rhinitis as a class effect. J Allergy Clin Immunol 121 (2008) 538-539
62. Baroody F.M., Shenaq D., DeTineo M., Wang J., and Naclerio R.M. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol 123 (2009) 1342-1348
63. Martin B.G., Ratner R.H., Hampel F.C., Andrews C.P., Toler T., and Wu W. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 28 (2007) 216-225
64. Andrews C.P., Martin B.G., Jacobs R.L., Mohar D.E., Diaz J.D., Amar N.J., et al. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc 30 (2009) 128-138
65. Jacobs R., Martin B., Hampel F., Toler W., Ellsworth A., and Philpot E. Effectiveness of fluticasone furoate 110 μg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin 25 (2009) 1393-1401
66. Friesen J.H. Regarding fluticasone furoate nasal spray and the control of ocular symptoms. J Allergy Clin Immunol 121 (2008) 265
67. Vasar M., Houle P.A., Douglass J.A., Meltzer E.O., Silvey M., Wu W., et al. Fluticasone furoate nasal spray: effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc 29 (2008) 313-321
68. Bonini S., Bonini S., Bucci M.G., Berruto A., Adriani E., Balsano F., et al. Allergen dose response and late symptoms in a human model of ocular allergy. J Allergy Clin Immunol 86 (1990) 869-876
69. Thompson A.K., Juniper E., and Meltzer E.O. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 85 (2000) 338-348